Paige

Paige and Microsoft Research unveil PRISM2: a whole-slide foundation model that analyzes tissue and understands it in context. From zero-shot predictions to clinician-ready reports, PRISM2 brings unparalleled versatility to diagnostics, biomarker discovery and multimodal patient outcome modeling. Trained on 2.3 million slides and paired with clinical reports, PRISM2 seamlessly integrates with Microsoft Phi-3, setting a new benchmark in performance, interpretability, and flexibility. https://lnkd.in/erXw8yYX

Last week, our Medical Vice President, Juan Antonio Retamero, joined Sara Pires de Oliveira from the Dutch Cancer Institute and Luca Di Tommaso, Professor of Pathology at Humanitas University in Italy, for a conversation on the state of digital pathology and the growing role of AI, both within their institutions and across Europe. While improved efficiency and time savings are clear advantages, the discussion pointed out additional advantages that come with embracing these technologies. Listen to their full conversation: https://lnkd.in/eDcMYJMd

At #ECDP2025, we shared a real-world success story that highlights the power of partnership in action! Our Medical Vice President, Dr. Juan Antonio Retamero, joined Rajendra Singh MD of PathPresenter and Mirelva Drost of Barco onstage to showcase how integrating best-in-class viewing, display, and AI-assisted diagnostics can transform the way cancer centers and labs operate. Together, our interoperable solution is already helping one of the world’s leading cancer centers streamline case review and keep the focus where it belongs, on patients.

Join us at #ECDP2025 in Barcelona, where we’ll collaborate with PathPresenter and Barco during the Interoperability Showcase. Together, we’ll present a real-world case study highlighting how our shared commitment to partnership and technical integration enabled the successful deployment of a fully interoperable digital pathology workflow at one of the world’s largest and most prestigious cancer centers.

Honored to take part in the first National Pathology Imaging Co-operative (NPIC) Summit and Roundtable today in Leeds, UK, where the focus was on the future of pathology imaging-based AI. Today’s discussions reflected the momentum and collaboration driving this space forward, from digital pathology adoption and multimodal data integration across the NHS to AI validation and the evolving landscape of diagnostic AI. We're excited to be part of the dialogue shaping the future! https://lnkd.in/e_q3yPju

A new study from the University of Florida College of Medicine – Jacksonville demonstrates how Paige Prostate can be a powerful clinical adjunct in one of pathology’s most ambiguous diagnoses, atypical small acinar proliferation (ASAP). In this retrospective study of 107 prostate biopsy cores diagnosed with ASAP: • Paige Prostate provided a consistent diagnosis in 85% of cases • Significantly reduced ASAP as a final diagnosis to just 15% • Showed strong agreement with both pathologists (66% and 75% concordance) • Statistically significant inter-rater reliability across AI and pathologist diagnoses • Outperformed historical pathologist-only concordance levels seen in prior studies (~59–63%) This independent study supports Paige Prostate can help pathologists reduce diagnostic uncertainty, standardize interpretation, and inform more confident management decisions for challenging prostate biopsy cases. A big thank you to Dr. Shahla Masood and her team for leading and carrying out this study! 📖 Read the full publication: https://lnkd.in/eVMEfTrf

At Paige, we’re using AI to solve cancer’s most critical challenges, going beyond diagnosis to support smarter, more personalized treatment decisions. To make this a reality, partnerships with organizations that share our vision are essential. That’s why we’re proud to announce a new collaboration with the BIG against breast cancer (Breast International Group), one of the largest global networks dedicated to academic breast cancer research. Together, we’re combining BIG’s clinical trial expertise and patient datasets with Paige’s AI technology to enhance biomarker detection, predict response to treatment, and enable the use of AI-driven tools for optimizing and personalizing therapy to make high-quality care more accessible. Learn more about the partnership and what it means for the future of breast cancer care: https://lnkd.in/e59Yi9f2

Our VP of AI Science, SIQI LIU, will deliver a keynote this week at the Medical Computer Vision Workshop at #CVPR2025 in Nashville. Siqi has been instrumental in shaping the next generation of AI at Paige and this session, he will share how industrial-scale pathology AI is being deployed to solve real-world challenges in cancer diagnostics and treatment. From expanding diagnostic access to enabling precision therapy selection, his talk will explore the increasing impact of AI across the healthcare ecosystem. If you’re attending CVPR, this is a session you won’t want to miss! https://cvpr.thecvf.com/

Teaming up with Lumea marks another important step toward accelerating the real-world adoption of AI in clinical pathology. By integrating our AI-assisted applications into Lumea’s end-to-end digital pathology platform, we’re delivering scalable, high-impact tools that help pathologists streamline workflows and expand access to advanced diagnostics without disrupting routine care.

Attending #ASCO2025 this weekend? Connect with members of the Paige team at Innovation Hub booth #8 or schedule a meeting with Djamilia Dierov, MPH and Razik Yousfi. They'll be onsite to discuss partnerships, foundation models, next-generation AI capabilities, and demo some of the exciting things we've been working on behind the scenes. See you in Chicago!